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Serum magnesium level and arterial calcification in end—stage renal
disease. In this paper we examine the relationship of serum levels of Ca,
P. Ca X P, P/Mg, Ca x P/Mg, alkaline phosphatase, and iPTH to the
development or regression of peripheral arterial calcifications (AC) in
44 patients with end—stage renal disease being treated by continuous
ambulatory peritoneal dialysis (CAPD). The average follow—up time of
this longitudinal study was 27 months (range 6—67 months). The patients
were divided into two groups: Group A, those showing one or more
increases of AC; and Group B, patients in whom AC either did not
develop or decreased during the follow—up. There was no significant
difference in serum Ca, P, Ca x P, alkaline phosphatase or iPTH
between the two groups. However, serum Mg was significantly lower in
Group A than in Group B (2.69 0.52 and 3.02 0.51 mg/dl,
respectively, P < 0.001), while the ratios P/Mg and Ca x P/Mg were
significantly higher. Our observations suggest that in end—stage renal
disease hypermagnesemia may retard the development of arterial
calcifications.
It has been suggested that arterial and other soft tissue
calcifications in end—stage renal disease are related to a high
serum calcium x phosphorus (Ca x P) product [1—5], while no
clear—cut relationship has been found with serum magnesium
[6—8]. On the other hand, treatment with 1 ,25dihydroxyvitamin
D3 (1 ,25-D3) has been implicated in the genesis of arterial
calcifications (AC) [1, 9]. Since we have developed certain
refinements in the radiologic technique for the study of AC, we
have re-examined the roles of serum Ca, P and Mg, and also the
relationship of 1,25-D3 treatment and hyperparathyroidism to
the genesis of AC in end—stage renal disease in this longitudinal
study.
Methods
The subjects of this study were 44 male patients aged 22 to 70
years suffering from end—stage renal disease, all treated with
CAPD for variable lengths of time between January 1980 and
June 1985. For inclusion in the study each patient had to have
the following investigations at the initial and at one or more
follow—up examinations: radiographic metabolic bone survey,
and serum Ca, P, Mg and alkaline phosphatase levels. Serum
Ca, P and alkaline phosphatase were measured monthly,
whereas Mg was measured every two months. Plasma iPTH
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was measured every six months in most patients. For the
purpose of this study we used only the values which were
closest to the date of the radiological investigation. Magnesium
was present in the dialysate fluid in all patients and the
concentration was 1.5 mEq/liter. None of the patients was
ingesting Mg at the time of the study. The number of exchanges
was four per day in most patients, and in those who had lower
creatinine, three per day.
Most commonly, the renal disease was due to diabetes
mellitus (20 patients), followed in frequency by chronic glomer-
ulonephritis, polycystic disease, hypertension and others. None
of the patients had undergone renal transplantation or parathy-
roidectomy. Table I provides information on the subjects and
the follow—up examinations.
Our radiographic skeletal survey included postero-anterior
fine—detail radiographs of both hands, both feet and lateral
views of both ankles. The soft tissues in these three areas were
scrutinized at x 6 magnification by a previously described
method of microradioscopy [10, 111 which permits detection
and a more reliable study of progression and regression of AC
than a mere visual inspection of ordinary medical radiographs
[12]. Examples of such progression and regression are shown in
Figures 1 and 2. A grading system was used for assessing the
extent of and changes in AC, similar to a previously described
grading of AC [13].
Subperiosteal resorption in hand bones (a radiologic manifes-
tation of hyperparathyroidism) was graded from 0 to 3 + by a
previously described microradioscopic method [14] with a slight
modification for follow-up purposes [15].
Serum Ca and Mg were measured by atomic absorption
spectrophotometry. Serum P and alkaline phosphatase were
measured by the Technicon Autoanalyzer (Technicon Instru-
ments, Tarrytown, New York, USA). Plasma iPTH was mea-
sured by a radioimmunoassay using an antiserum (GP-l) di-
rected against both amino and carboxy terminal parts of the
PTH molecule [16].
The dose and duration of 1 ,25-D3 treatment and oral calcium
supplementation were also recorded.
Results
The values of serum Ca, P, Mg, Ca >< P, P:Mg, Mg X Ca,
Mg:Ca, (Ca x P):Mg, alkaline phosphatase and plasma iPTH
were compared by analysis of variance between two groups of
patients: 1) Group A, those who showed one or more increases
of AC; and 2) Group B, patients in whom AC either did not
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Table 1. Subjects and follow—up inforrnation on peripheral arterial calcifications (AC)
Average Average N of observations
age Age follow—up Range Total N of in which changes
N years range months (months) observations occurred
AC appeared or progressed (Group A) 22 49.0 21—69 32.0 6—57 111 42
No AC developed (Group B1) 17 47.2 24—68 21.1 10—51 68 N/A
AC regressed (Group B2) 3 36.7 22—44 20.3 13—24 10 5
AC first progressed, then regressed 2 37.5 24—51 38.5 43—67 13 5
Total 44 46.9 21—69 27.3 6—67 202 52
Fig. 1. Progression of arterial calcifications in the first metacarpal
artery in a 29-year—old female patient after 5 years of follow—up,
magnification >< 6. Note the narrowing of the lumen at arrows in B, not
detectable in the regular unmagnified radiograph. The patient required
amputation of a part of this hand due to subsequent gangrene.
develop (B1), or decreased (B2) during the follow—up. The mean
values and standard deviations for each of the variables for
Groups A and B are shown in Table 2 and for subgroups B1 and
B2 in Table 3. As shown in Table 2, the analysis of variance
revealed no significant differences for Ca, P, Ca x P. alkaline
phosphatase and iPTH between groups A and B. Serum Mg
levels, however, were significantly higher in Group B than in
Group A (P < 0.001, Table 2), and the ratios and products
including Mg also differed significantly between Groups A and
B.
Figure 3 depicts the individual values of serum Mg in Group
A (AC progressed) and in the two subgroups B (AC did not
Fig. 2. Marked regression of arterial calcifications posterior to the
ankle in a 39-year-old male patient after 3 years of follow up,
unmagnified. Note the segmental break—up of calcifications in the
posterior tibial artery and complete disappearance of calcifications in
many of the smaller arteries.
develop) and B2 (AC regressed), in relation of our normal range
of serum Mg (1.7 to 2.6 mg/dl). A comparison of the frequency
of observations between Group A and Group B (B1+B2) re-
vealed that when there was hypermagnesemia, progressions of
AC occurred in 22 of 86 observations, while non-development
or regressions were noted in 64 of 86 observations. Within the
normomagnesemic range, however, the respective numbers
were 22 of 34 and 12 of 34, the difference between these two
sample proportions being significant by chi—square test
(chi—square = 14.68, P < 0.001). When using various cut—off
values for serum Mg, the value of our normal upper limit
yielded the highest chi—square value, that is, the normal upper
limit of serum Mg may be presumed to represent the degree of
hypermagnesemia necessary to prevent or reduce AC.
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Table 2. Biochemical findings (mean SD) at each observation when
peripheral arterial calcifications progressed (Group A), and when they
did not develop or regressed (Group B)
Normal
Group A Group B ranges
N of patients 24' 22C
N of observations 44 76
Serum Ca mg/dl 9.06 0.68 9.04 0.78 8.8—10.3
Serum P mg/dl 5.96 1.57 5.72 1.43 2.6—4.5
SerumMgmg/dl 2.69 3.02±0Mb 1.7—2.6
Ca x p 54.0 14.8 51.5 13.0 22.9—46.3
P:Mg 2.35 0.95 1.94 0.60a 1.0—2.6
Mg x Ca 24.3 4.84 27.5 553b 15.0—26.8
Mg:Ca 0.30 0.06 0.34 0•06b 3.4—6.1
Ca x p 21.2 8.65 17.5 5.l4' 8.8—27.2
Mg
Alkaline phosphtase I.U. 128.9 106.7 104.6 78.0 35—100
iPTHpM/literd 48.1 56.7 59.5 94.6 0—25
' P < 0.01
b P < 0.001
The two patients in whom AC first progressed and then regressed
(Table 1) are included in both Groups A and Bd One or more observations missing in 23 patients
Fig. 3. Comparison of serum Mg values and Ca x P products in three
groups of patients (AC = arterial calcificarions): AC = Group A; AC0 = Group B1; AC = Group B2.
ND DM (all ND) ND DM
av. age 47.2 49.3 46.4 37.5 36.6
5—
Fig. 4. Comparison of serum Mg values in diabetics and non-diabetics
of similar age, and between non-diabetics whose arterial calcfications
progressed and those who did not develop any during the follow—up (in
the latter, average values for each patient are shown).
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Since Ca x P product is often considered the most important
biochemical determinant in the development and progression of
soft tissue calcifications fl—5], we have in Figure 3 also com-
pared the values of individual observations of Ca x P in relation
to their normal ranges. A comparison of the frequency of
observations between Group A and Group B (B1+B2) revealed
that when Ca x P product was above the normal range,
progression of AC occurred in 30 observations, and non-
development or regressions in 53 observations. However, when
Ca x P was within the normal range, the respective numbers
were 14 and 23, the difference being statistically not significant
(chi—square = 0.0045). Thus, a high serum Mg level is a much
better biochemical index than a high Ca x P product for
discriminating between those in whom AC regressed or did not
develop during the follow—up (Group B) than those in whom
they progressed (Group A).
It is also apparent from Table 2 that the differences in the
means of Ca x P between groups A and B were entirely due to
differences in P rather than Ca. One would therefore expect that
the P:Mg ratio should be the best discriminator between those
who developed AC and those who did not. However, the
statistical significances between the groups were actually lower
for P:Mg than for Mg alone. Surprisingly, they were also lower
for P:Mg than for Mg:Ca and Mg x Ca (Tables 2 and 3).
As shown in Table 3 and Figure 3, comparison of values
between subgroups B1 (no development of AC) and B2 (regres-
sion of AC) showed that in Group B2 the mean serum Mg was
higher and serum P lower than in Group B1. However, these
differences were not statistically significant, probably because
of the small number of observations in Group B2 (Table 3).
Interestingly, both the alkaline phosphatase and iPTH were also
higher in Group B2, although only the former attained border-
line statistical significance.
Since AC occur and progress more commonly in patients
with diabetes mellitus than in non-diabetics with end—stage
renal disease [13], we divided Group A into patients with
diabetes (N of observations = 24) and those without (N of
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observations = 20), and found no significant difference in their
serum Mg levels (Fig. 4). Interestingly, none of those who did
not develop AC during the follow—up was diabetic. Comparison
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Table 3. Biochemical findings (mean SD) at each observation when peripheral arterial calcifications did not develop (Group B,) and when
they regressed (Group B2)
Group B, Group B2
P valuesa
A vs. B A vs. B, A vs. B2 B, vs. B2
N of patients 17 5
N of observations 68 8
Serum Ca mg/dl 9.01 0.76 9.26 0.97 NS NS NS NS
Serum P mgldl 5.76 1.46 5.36 1.22 NS NS NS NS
Serum Mg mg/dl 3.00 0.45 3.29 0.83 <0.001 <0.01 <0.01 NS
Ca x P 51.8 13.2 49.5 11.8 NS NS NS NS
P:Mg 1.97 0.61 1.69 0.47 <0.01 <0.05 <0.05 NS
Mg >< Ca 27.1 5.42 30.2 6.11 <0.001 <0.01 <0.01 NS
Mg:Ca 0.33 0.05 0.36 0.13 <0.001 <0.01 <0.01 NS
Ca x P 17.7 5.15 15.8 5.09 <0.01 <0.01 <0.05 NS
Mg
Alkaline phosphatase I.U. 95.6 71.5 180.4 94.2 NS NS NS <0.05
iPTHpM/literb 57.3 94.1 85.0 107.7 NS NS NS NS
a The means SD for Groups A and B were shown in Table 2.
b One or more observations missing in 7 patients
of Mg values of this group with non-diabetics who developed
AC, also similar in age (Fig. 4), showed that the mean value was
significantly lower in the latter group (Student's t-test, P <
0.05). In the small group with decreasing AC, all except one
observation showed distinctly elevated values of serum Mg;
surprisingly, five of eight observations were in diabetics.
An assessment of a possible influence of I ,25-D3 on the
development of AC showed that at the times of progressions of
AC, l,25-D3 had been given to the patients prior to 32 of 42
observations. In contrast, those who did not develop AC
(Group B1) had been given l,25-D3 prior to only 29 of 60
observations. (Some observations were not included because of
insufficient information on 1 ,25-D3 treatment). The difference
between these two sample proportions was statistically signifi-
cant (chi—square 7.71, P < 0.01). Thus, l,25-D3 treatment
also appears to promote the progression of arterial calcifica-
tions.
A comparison of serum Mg values in those who had received
l,25-D3 and those who had not showed no significant differ-
ences by Student's t-test. In patients receiving l,25-D3 supple-
mentation, a comparison of serum Mg levels between those
with progressive AC (mean value 2.78) and those in whom no
AC developed (mean value 3.03) revealed no significant differ-
ence (t = 1.90,P < 0.1). It thus appears that 1 ,25-D3 and Mg are
independent factors with respect to the development of arterial
calcifications.
Only six patients had received calcium supplements, three
with progressive AC and three without development of any.
Although the biochemical parameters of parathyroid func-
tion—iPTH and alkaline phosphatase—did not show any signif-
icant difference between Group A and B (Table 2), a compari-
son of the grades of radiological subperiosteal resorption be-
tween Groups A and B1 showed that the mean grade of 1.30 in
the former group was significantly higher than that of 0.92 in the
latter by Student's t-test (P < 0.05). This suggests that hyper-
parathyroidism, at the skeletal level, is slightly more prevalent
in patients with progressive AC than in those without AC.
Interestingly, in Group B2, in which AC regressed, the average
grade of 1.38 of subperiosteal resorption was actually the
highest. This, however, can be explained by the finding of a
previous study that subperiosteal resurption is significantly
more marked in younger than in older patients with end—stage
renal disease [15]. The average age in this small subgroup of five
patients was more than 10 years lower than in other subgroups
(Table I).
Hyperparathyroidism is known to be less prevalent in diabet-
ics than in non-diabetics, both by biochemical and radiological
criteria [17, 18]. We therefore compared grading of subperios-
teal resorption in the non-diabetic Group with that of the
non-diabetics in Group A and found a significant difference
between these two groups (means of 0.92 and 1.63, respec-
tively, P < 0.01). This indicates an increased incidence of
hyperparathyroidism in patients with progressive AC compared
to those without.
Discussion
Although it has been previously suggested that a high serum
Ca x P product is one of the principal factors in the develop-
ment of AC in end—stage renal disease [1—5], there have been
some recent studies [6—8] that have failed to show any clear—cut
relationship. Thus, in the study by DeFrancisco et al [8], the
presence or absence of soft tissue calcifications in 62 patients
with secondary hyperparathyroidism of chronic renal failure
was found to be unrelated to serum Ca, P, Ca x P, Mg, alkaline
phosphatase, plasma iPTH levels, radiologic erosions, severity
of histologic osteitis fibrosa or parathyroid gland weight.
Our findings have also shown poor relationship between the
AC and Ca, P, Ca X P, alkaline phosphatase and iPTH, but a
highly significant relationship with serum Mg levels. The rea-
sons why such relationships have not been detected previously
appear largely methodological. In the present study, which is a
longitudinal rather than cross—sectional one, we have made use
of fine—detail radiographs enabling magnification and therefore
a more confident recognition of slight changes in AC.
In accordance with previous findings of frequent hypermag-
nesemia in patients with end—stage renal disease [7, 8, 19—21],
hypermagnesemia was also common in our patients. The mean
serum Mg, however, was lower in those in whom AC pro-
gressed than in others in whom AC did not develop (Fig. 3); in
the small group of observations where AC regressed, the mean
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serum Mg was even higher. On the other hand, the higher than
normal mean serum Ca x P values did not differ significantly
among the three groups (Fig. 3).
Although it has been suggested that serum Mg levels poorly
reflect the intracellular Mg content and that in patients with
renal failure hypermagnesemia may be accompanied by tissue
Mg depletion [22—24] or normal tissue Mg content [25], it is
nevertheless possible that the lower than average serum Mg
levels seen when AC progresses may facilitate the calcification
in the media of the arteries since Mg is a potent inhibitor of the
calcification process [26—28].
Another possibility is that the higher serum Mg prevented AC
by suppressing the secretion of PTH [29—32]. This view is not
supported by our data in that iPTH levels did not differ
significantly between any of the subgroups and subperiosteal
resorption was actually greater in those in whom AC were
progressive.
As has been previously suggested [9], l-alpha-hydroxychole-
calciferol treatment may promote the development of AC in
uremic rats. Our findings indicate that this mechanism may also
be operative in humans suffering from end—stage renal disease
in that treatments with l,25-D3 had been more frequent in
patients with progressive AC than in those without develop-
ment of AC. This effect of I ,25-D3, however, appeared to be
independent of that of serum magnesium.
It has been shown that Mg is a potent inhibitor of the
calcification process [26—28] and that experimental Mg defi-
ciency appears to promote AC [33—34]. It has also been sug-
gested that a high Mg intake (such as, hard versus soft drinking
water) may have an inhibitory effect on atherogenesis [35—37]
and on acute cardiac ischemic attacks [38—41]. Furthermore,
peroral magnesium hydroxide therapy has significantly im-
proved the performance in patients with intermittent claudica-
tion [42]. These observations support the view that hypermag-
nesemia in end—stage renal disease may also be a causal factor
in retarding the development of arterial calcifications.
It is often stated that arterial medial calcifications (Moncke-
berg's sclerosis) are of little clinical consequence, being often
found in asymptomatic patients [2, 43—50]. These authors have
ignored evidence (including the original observations by
Monckeberg [51]) clearly demonstrating that at least in chronic
renal failure and in diabetes mellitus, AC in the media of
medium—sized and small vessels are often very marked, and
may displace intima causing luminal narrowing and leading to
ischemia and gangrene [52—62]. One of the most convincing of
these studies included histologic examinations of 20 amputated
limbs by Ferrier [54]. He found that, out of a total of 16 arteries
with advanced medial calcification, 15 were obstructed. The
calcifications were more frequent in diabetic than in non-
diabetic patients. In one of our recent studies on diabetics with
end—stage renal disease, the incidence of amputations was five
of 71(7%) and very marked AC were found in all five patients
[13]. Others have reported an even higher incidence of ampu-
tations (up to 21%) in diabetics with end—stage renal disease
[63].
On the basis of these and similar observations, and in order to
restore the real meaning of "Monckeberg's sclerosis", we have
recently suggested a concept of two clinically and histologically
different types of medial calcifications [12]: 1) a benign slowly
progressive, essentially asymptomatic form with thin medial
calcifications and little or no narrowing of the arterial lumen;
and 2) a malignant, rapidly progressive type in which massive
and extensive medial calcifications may displace the internal
elastica toward the lumen (and even break through into the
intima) causing luminal narrowing. Although the observations
leading to these conclusions have been made in the peripheral
arteries, they may also be applicable to the coronary arteries
since, contrary to some reports [45, 48, 64], medial calcifica-
tions are indeed found in the arteries of the heart [65—70], thus
possibly further contributing to the known high prevalence of
cardiovascular complications in chronically dialyzed patients
[71—73].
It therefore appears that further studies on AC are indeed
necessary, including those concerned with possible protective
role of modest hypermagnesemia. The serum Mg levels rarely
exceeded 4 mg/dl in our patients, well below the levels of
reported acute Mg toxicity [74—76]. The possibility, however,
that such hypermagnesemia in patients with chronic renal
failure [29—32] also increases the concentration of Mg in bone
and that this may interfere with the normal mineralization
process [77, 78], should also be further explored.
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